Table 2 Patient, Tumor and Treatment Characteristics
Parameter | N = 31 |
|---|---|
Age (yrs), median (range) | 47 (18–73) |
Sex | |
 Male | 18 |
 Female | 13 |
KPS at time of reRT | |
  ≤ 50 | 1 |
 50–70 | 5 |
  > 70 | 25 |
Original histology | |
 WHO grade IV | 18 |
 WHO grade III | 5 |
 WHO grade II | 7 |
 Gliosarcoma | 1 |
Original tumor location | |
 Frontal | 13 |
 Parietal | 5 |
 Temporal | 3 |
 Occipitoparietal | 1 |
 Temporoparietal | 3 |
 Frontotemporal | 2 |
 Brainstem/Cerebellum | 3 |
 Other | 1 |
Recurrence location wrt to the 80% isodose line | |
 Within | 25 |
 Outside | 6 |
  Other hemisphere | 1 |
  Brainstem | 2 |
  4th ventricle/post fossa | 2 |
  Adjacent Lobe | 1 |
DFS median (range)(months) | 33.7 (11.4–174) |
Tissue diagnosis prior to re-RT | 22 |
Concurrent agent administration | 13 |
 Temozolomide alone | 4 |
 Bevacizumab alone | 5 |
 Temozolomide and Bevacizumab | 1 |
 Other | 3 |
Management upon progression after re-RT | |
 Bevacizumab | 8 |
 BSC | 20 |
 Other (BCNU, study) | 3 |